{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T20:37:00Z","timestamp":1777063020086,"version":"3.51.4"},"reference-count":170,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GLOBALDOC Project \u2010 CUP H96J17000160002 approved with A.D. n. 9 of January 18, 2017, from Puglia Region, financed under the Action Plan for Cohesion approved with Commission decision C (2016)","award":["1417"],"award-info":[{"award-number":["1417"]}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20441"],"award-info":[{"award-number":["20441"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Apulian Regional project: medicina di precisione","award":["06062019"],"award-info":[{"award-number":["06062019"]}]},{"name":"Association against lymphomas \u201cIl Sorriso di Antonio\u201d, Corato, Italy","award":["1"],"award-info":[{"award-number":["1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), accounting for about 40% of all cases of NHL. Analysis of the tumor microenvironment is an important aspect of the assessment of the progression of DLBCL. In this review article, we analyzed the role of different cellular components of the tumor microenvironment, including mast cells, macrophages, and lymphocytes, in the tumor progression of DLBCL. We examined several approaches to confront the available pieces of evidence, whereby three key points emerged. DLBCL is a disease of malignant B cells spreading and accumulating both at nodal and at extranodal sites. In patients with both nodal and extranodal lesions, the subsequent induction of a cancer-friendly environment appears pivotal. The DLBCL cell interaction with mature stromal cells and vessels confers tumor protection and inhibition of immune response while delivering nutrients and oxygen supply. Single cells may also reside and survive in protected niches in the nodal and extranodal sites as a source for residual disease and relapse. This review aims to molecularly and functionally recapitulate the DLBCL\u2013milieu crosstalk, to relate niche and pathological angiogenic constitution and interaction factors to DLBCL progression.<\/jats:p>","DOI":"10.3390\/cancers12071869","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T11:03:23Z","timestamp":1594724603000},"page":"1869","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["New Insights into Diffuse Large B-Cell Lymphoma Pathobiology"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-9698","authenticated-orcid":false,"given":"Antonio Giovanni","family":"Solimando","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine \u2018G. Baccelli\u2019, University of Bari Medical School, 70124 Bari, Italy"},{"name":"Istituto di Ricovero e Cura a Carattere Scientifico-IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d of Bari, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7752-0368","authenticated-orcid":false,"given":"Tiziana","family":"Annese","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neurosciences, and Sensory Organs, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Tamma","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neurosciences, and Sensory Organs, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4792-3545","authenticated-orcid":false,"given":"Giuseppe","family":"Ingravallo","sequence":"additional","affiliation":[{"name":"Department of Emergency and Transplantation, Pathology Section, University of Bari Medical School, 70100 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-5338","authenticated-orcid":false,"given":"Eugenio","family":"Maiorano","sequence":"additional","affiliation":[{"name":"Department of Emergency and Transplantation, Pathology Section, University of Bari Medical School, 70100 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4567-8216","authenticated-orcid":false,"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine \u2018G. Baccelli\u2019, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[{"name":"Department of Emergency and Transplantation, Hematology Section, University of Bari Medical School, 70100 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4768-8431","authenticated-orcid":false,"given":"Domenico","family":"Ribatti","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Neurosciences, and Sensory Organs, University of Bari Medical School, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer. [Revised 4th ed.]. World Health Organization Classification of Tumours."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.semdp.2011.04.001","article-title":"Molecular pathogenesis of diffuse large B-cell lymphoma","volume":"28","author":"Schneider","year":"2011","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive Nuclear Factor \u03baB Activity Is Required for Survival of Activated B Cell\u2013like Diffuse Large B Cell Lymphoma Cells","volume":"194","author":"Davis","year":"2001","journal-title":"J. Exp. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-\u03baB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1756-8722-4-31","article-title":"High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma","volume":"4","author":"Zl","year":"2011","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-14-0683","article-title":"Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma","volume":"20","author":"Ok","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","article-title":"Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas","volume":"111","author":"Ding","year":"2008","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-\u03baB pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Lam","year":"2008","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/neuonc\/nos139","article-title":"Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma","volume":"14","author":"Doucette","year":"2012","journal-title":"Neuro-Oncology"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gao, P., Niu, N., Wei, T., Tozawa, H., Chen, X., Zhang, C., Zhang, J., Wada, Y., Kapron, C.M., and Liu, J. (2017). The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis. Oncotarget, 8.","DOI":"10.18632\/oncotarget.19932"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal Gene Signatures in Large-B-Cell Lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: Optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","article-title":"T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells","volume":"128","author":"Azzaoui","year":"2016","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1159\/000487288","article-title":"Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma","volume":"45","author":"Ji","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3324\/haematol.2017.177162","article-title":"Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment","volume":"103","author":"Rudelius","year":"2018","journal-title":"Haematologica"},{"key":"ref_22","unstructured":"Solimando, A.G., Da Vi\u00e0, M.C., Leone, P., Borrelli, P., Croci, G.A., Tabares, P., Brandl, A., Di Lernia, G., Bianchi, F.P., and Tafuri, S. (2020). Halting the vicious cycle within the multiple myeloma ecosystem: Blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression. Haematologica."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/6820241","article-title":"A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche","volume":"2020","author":"Solimando","year":"2020","journal-title":"J. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.stem.2015.02.015","article-title":"The cancer stem cell niche: How essential is the niche in regulating stemness of tumor cells?","volume":"16","author":"Plaks","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.leukres.2015.11.001","article-title":"Targeting B-cell non Hodgkin lymphoma: New and old tricks","volume":"42","author":"Solimando","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/asheducation-2017.1.295","article-title":"Current treatment of double hit and double expressor lymphoma","volume":"2017","author":"Reagan","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"ref_29","first-page":"1470","article-title":"MYC\/BCL2\/BCL6 triple hit lymphoma: A study of 40 patients with a comparison to MYC\/BCL2 and MYC\/BCL6 double hit lymphomas","volume":"31","author":"Huang","year":"2018","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/annonc\/mdw029","article-title":"Breakthrough therapies in B-cell non-Hodgkin lymphoma","volume":"27","author":"Cheah","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-019-0752-3","article-title":"Novel and emerging therapies for B cell lymphoma","volume":"12","author":"Ayyappan","year":"2019","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","article-title":"Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma","volume":"51","author":"Meyer","year":"2019","journal-title":"Immunity"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12935-017-0439-1","article-title":"EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP","volume":"17","author":"Li","year":"2017","journal-title":"Cancer Cell Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","article-title":"Liquid biopsy: Monitoring cancer-genetics in the blood","volume":"10","author":"Crowley","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13046-020-01601-2","article-title":"Liquid biopsy and tumor heterogeneity in metastatic solid tumors: The potentiality of blood samples","volume":"39","author":"Russano","year":"2020","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Krebs, M., Solimando, A.G., Kalogirou, C., Marquardt, A., Frank, T., Sokolakis, I., Hatzichristodoulou, G., Kneitz, S., Bargou, R., and K\u00fcbler, H. (2020). miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro. J. Clin. Med., 9.","DOI":"10.3390\/jcm9030670"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease - latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Desantis, V., Saltarella, I., Lamanuzzi, A., Melaccio, A., Solimando, A.G., Mariggi\u00f2, M.A., Racanelli, V., Paradiso, A., Vacca, A., and Frassanito, M.A. (2020). MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093084"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Di Lernia, G., Leone, P., Solimando, A.G., Buonavoglia, A., Saltarella, I., Ria, R., Ditonno, P., Silvestris, N., Crudele, L., and Vacca, A. (2020). Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020552"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Leone, P., Buonavoglia, A., Fasano, R., Solimando, A.G., De Re, V., Cicco, S., Vacca, A., and Racanelli, V. (2019). Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122030"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Larrabeiti-Etxebarria, A., Lopez-Santillan, M., Santos-Zorrozua, B., Lopez-Lopez, E., and Garcia-Orad, A. (2019). Systematic Review of the Potential of MicroRNAs in Diffuse Large B Cell Lymphoma. Cancers, 11.","DOI":"10.3390\/cancers11020144"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nrclinonc.2015.77","article-title":"CtDNA\u2014Identifying cancer before it is clinically detectable","volume":"12","author":"Hutchinson","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","article-title":"Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin","volume":"164","author":"Snyder","year":"2016","journal-title":"Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminhematol.2015.01.005","article-title":"The genetic landscape of diffuse large B-cell lymphoma","volume":"52","author":"Pasqualucci","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Da Vi\u00e0, M.C., Cicco, S., Leone, P., Di Lernia, G., Giannico, D., Desantis, V., Frassanito, M.A., Morizio, A., and Delgado Tascon, J. (2019). High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment. J. Clin. Med., 8.","DOI":"10.20944\/preprints201906.0145.v1"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2353\/jmoldx.2006.050083","article-title":"FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue","volume":"8","author":"Ventura","year":"2006","journal-title":"J. Mol. Diagn. JMD"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/10428190500051208","article-title":"De novo CD5-positive diffuse large B-cell lymphoma of the skin arising in chronic limb lymphedema","volume":"46","author":"Dargent","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"20465","DOI":"10.1038\/srep20465","article-title":"The distinct clinical features and prognosis of the CD10+MUM1+ and CD10\u2212Bcl6\u2212MUM1\u2212 diffuse large B-cell lymphoma","volume":"6","author":"Lu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1182\/asheducation-2014.1.90","article-title":"Diagnosis of \u201cdouble hit\u201d diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: When and how, FISH versus IHC","volume":"2014","author":"Swerdlow","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/10428190802140055","article-title":"Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma","volume":"49","author":"Hasselblom","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood-2018-99-117636","article-title":"New Genomic Model Integrating Clinical Factors and Gene Mutations to Predict Overall Survival in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP","volume":"132","author":"Song","year":"2018","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","article-title":"Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL","volume":"133","author":"Bojarczuk","year":"2019","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2012.066209","article-title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: A report from an International DLBCL rituximab-CHOP Consortium Program Study","volume":"98","author":"Visco","year":"2013","journal-title":"Haematologica"},{"key":"ref_66","unstructured":"Seibold, M., St\u00fchmer, T., Kremer, N., Mottok, A., Scholz, C.-J., Schlosser, A., Leich, E., Holzgrabe, U., Br\u00fcnnert, D., and Barrio, S. (2019). RAL GTPases mediate multiple myeloma cell survival and are activated independently of oncogenic RAS. Haematologica."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1182\/blood-2019-131250","article-title":"Validation of the Genetically-Defined DLBCL Subtypes and Generation of a Parsimonious Probabilistic Classifier","volume":"134","author":"Chapuy","year":"2019","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/10428190902893835","article-title":"Targeting angiogenesis: A novel, rational therapeutic approach for non-Hodgkin lymphoma","volume":"50","author":"Ruan","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1093\/annonc\/mdy450","article-title":"Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue","volume":"29","author":"Ciavarella","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/stem.1556","article-title":"CD44 Expressed on Cancer-Associated Fibroblasts Is a Functional Molecule Supporting the Stemness and Drug Resistance of Malignant Cancer Cells in the Tumor Microenvironment: Tumor Stromal CD44","volume":"32","author":"Kinugasa","year":"2014","journal-title":"Stem Cells"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/path.5187","article-title":"Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes","volume":"247","author":"Frassanito","year":"2019","journal-title":"J. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bbamcr.2015.11.003","article-title":"Tumor microenvironment (TME)-driven immune suppression in B cell malignancy","volume":"1863","author":"Nicholas","year":"2016","journal-title":"Biochim. Biophys. Acta BBA Mol. Cell Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2141.2007.06612.x","article-title":"Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma","volume":"138","author":"Berglund","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1007\/s12032-011-0123-6","article-title":"High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma","volume":"29","author":"Cai","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/1-4020-7920-6_9","article-title":"Angiogenesis in Leukemia and Lymphoma","volume":"121","author":"Finn","year":"2004","journal-title":"Hematopathology in Oncology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1593\/neo.121962","article-title":"The Role of Angiogenesis in Human Non-Hodgkin Lymphomas","volume":"15","author":"Ribatti","year":"2013","journal-title":"Neoplasia"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/onc.2014.403","article-title":"The tumor microenvironment shapes hallmarks of mature B-cell malignancies","volume":"34","author":"Shain","year":"2015","journal-title":"Oncogene"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int. Rev. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41598-018-37273-4","article-title":"Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma","volume":"9","author":"Fornecker","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"60698","DOI":"10.18632\/oncotarget.10849","article-title":"Microenvironment drug resistance in multiple myeloma: Emerging new players","volume":"7","author":"Desantis","year":"2016","journal-title":"Oncotarget"},{"key":"ref_81","first-page":"169","article-title":"Drug resistance mediated by cellular stress response to the microenvironment of solid tumors","volume":"14","author":"Tomida","year":"1999","journal-title":"Anticancer. Drug Des."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2011-03-345272","article-title":"Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment","volume":"118","author":"Alizadeh","year":"2011","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Argentiero, A., De Summa, S., Di Fonte, R., Iacobazzi, R.M., Porcelli, L., Da Vi\u00e0, M., Brunetti, O., Azzariti, A., Silvestris, N., and Solimando, A.G. (2019). Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Cancers, 11.","DOI":"10.20944\/preprints201906.0228.v1"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","article-title":"T-regulatory cells: Key players in tumor immune escape and angiogenesis","volume":"72","author":"Facciabene","year":"2012","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e1486949","DOI":"10.1080\/2162402X.2018.1486949","article-title":"Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients","volume":"8","author":"Leone","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/152581603321210091","article-title":"Angiogenesis and Anti-Angiogenesis in Hematological Malignancies","volume":"12","author":"Ribatti","year":"2003","journal-title":"J. Hematother. Stem Cell Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00277-018-3293-x","article-title":"Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma","volume":"97","author":"Desantis","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_88","first-page":"CD003407","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"12","author":"Tonia","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/leu.2015.302","article-title":"A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma","volume":"30","author":"Suhasini","year":"2016","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-07-6621","article-title":"Myeloid-Derived Suppressor Cells Promote Cross-Tolerance in B-Cell Lymphoma by Expanding Regulatory T Cells","volume":"68","author":"Serafini","year":"2008","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"90808","DOI":"10.18632\/oncotarget.19385","article-title":"VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers","volume":"8","author":"Mourah","year":"2017","journal-title":"Oncotarget"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1182\/blood-2009-06-225326","article-title":"The microenvironment in mature B-cell malignancies: A target for new treatment strategies","volume":"114","author":"Burger","year":"2009","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2019-126674","article-title":"Adhesion-Mediated Multiple Myeloma (MM) Disease Progression: Junctional Adhesion Molecule a Enhances Angiogenesis and Multiple Myeloma Dissemination and Predicts Poor Survival","volume":"134","author":"Solimando","year":"2019","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/leu.2016.161","article-title":"Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells","volume":"30","author":"Pizzi","year":"2016","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/0008-5472.CAN-10-2380","article-title":"STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma","volume":"71","author":"Scuto","year":"2011","journal-title":"Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.bjc.6600742","article-title":"Vascular patterns in reactive lymphoid tissue and in non-Hodgkin\u2019s lymphoma","volume":"88","author":"Passalidou","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2010.037408","article-title":"High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy","volume":"96","author":"Colomo","year":"2011","journal-title":"Haematologica"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.17219\/acem\/61427","article-title":"Angiogenesis in CD5-positive Diffuse Large B Cell Lymphoma: A Morphometric Analysis","volume":"25","author":"Gierej","year":"2016","journal-title":"Adv. Clin. Exp. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood.V110.11.53.53","article-title":"Prognostic Significance of VEGF, VEGF Receptors, and Microvessel Density in Diffuse Large B Cell Lymphoma Treated with Anthracycline-Based Chemotherapy","volume":"110","author":"Gratzinger","year":"2007","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/10428190601083241","article-title":"Angiogenesis in non-Hodgkin\u2019s lymphoma: Clinico-pathological correlations and prognostic significance in specific subtypes","volume":"48","author":"Bendix","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4103\/0973-1482.146086","article-title":"Abnormal vascular endothelial growth factor protein expression may be correlated with poor prognosis in diffuse large B-cell lymphoma: A meta-analysis","volume":"12","author":"Jiang","year":"2016","journal-title":"J. Cancer Res. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1080\/10428194.2017.1300893","article-title":"Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma","volume":"58","author":"Yoon","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00432-007-0294-x","article-title":"The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: A retrospective study of 97 patients","volume":"134","author":"Ganjoo","year":"2008","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1349-7006.2011.02168.x","article-title":"VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma","volume":"103","author":"Kim","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Borges, N.M., do Elias, M.V., Fook-Alves, V.L., Andrade, T.A., de Conti, M.L., Macedo, M.P., Begnami, M.D., Campos, A.H.J.F.M., Etto, L.Y., and Bortoluzzo, A.B. (2016). Angiomirs expression profiling in diffuse large B-Cell lymphoma. Oncotarget, 7.","DOI":"10.18632\/oncotarget.6624"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1038\/s41375-019-0478-9","article-title":"Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma","volume":"33","author":"Lupino","year":"2019","journal-title":"Leukemia"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0163-7258(00)00084-X","article-title":"Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors","volume":"88","author":"Pyne","year":"2000","journal-title":"Pharmacol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1182\/blood-2004-01-0226","article-title":"Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo","volume":"104","author":"Wang","year":"2004","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/10428190310001607151","article-title":"The Interplay Between C-Myc Oncogene Expression and Circulating Vascular Endothelial Growth Factor (sVEGF), Its Antagonist Receptor, Soluble Flt-1 in Diffuse Large B Cell Lymphoma (DLBCL): Relationship to Patient Outcome","volume":"45","author":"Aref","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/10428190902856808","article-title":"A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108","volume":"50","author":"Stopeck","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.leukres.2014.09.007","article-title":"Microvascular density, CD68 and tryptase expression in human Diffuse Large B-Cell Lymphoma","volume":"38","author":"Marinaccio","year":"2014","journal-title":"Leuk. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10238-015-0354-5","article-title":"T cells, mast cells and microvascular density in diffuse large B cell lymphoma","volume":"16","author":"Marinaccio","year":"2016","journal-title":"Clin. Exp. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00277-010-0964-7","article-title":"Clinical impact of bulky mass in the patient with primary extranodal diffuse large B cell lymphoma treated with R-CHOP therapy","volume":"89","author":"Song","year":"2010","journal-title":"Ann. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tranon.2018.12.008","article-title":"STAT-3 RNAscope Determination in Human Diffuse Large B-Cell Lymphoma","volume":"12","author":"Tamma","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/10428194.2019.1678154","article-title":"STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas","volume":"61","author":"Tamma","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Sircar, A., Chowdhury, S.M., Hart, A., Bell, W.C., Singh, S., Sehgal, L., and Epperla, N. (2020). Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030904"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3324\/haematol.2017.184192","article-title":"Hide or defend, the two strategies of lymphoma immune evasion: Potential implications for immunotherapy","volume":"103","author":"Houot","year":"2018","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.yexcr.2016.07.003","article-title":"Y-box-binding protein-1 (YB-1) promotes cell proliferation, adhesion and drug resistance in diffuse large B-cell lymphoma","volume":"346","author":"Miao","year":"2016","journal-title":"Exp. Cell Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1084\/jem.20090397","article-title":"Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion","volume":"207","author":"Huang","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_121","first-page":"1929","article-title":"The expression of heparin-binding epidermal growth factor-like growth factor by regulatory macrophages","volume":"182","author":"Edwards","year":"2009","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Rao, L., Giannico, D., Leone, P., Solimando, A.G., Maiorano, E., Caporusso, C., Duda, L., Tamma, R., Mallamaci, R., and Susca, N. (2020). HB-EGF-EGFR Signaling in Bone Marrow Endothelial Cells Mediates Angiogenesis Associated with Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12010173"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood-2005-05-1929","article-title":"Functional analysis of HGF\/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma","volume":"107","author":"Tjin","year":"2006","journal-title":"Blood"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-13-0039","article-title":"Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma","volume":"19","author":"Moschetta","year":"2013","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1158\/1078-0432.CCR-14-0847","article-title":"A HGF\/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target","volume":"20","author":"Ferrucci","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"13366","DOI":"10.18632\/oncotarget.24351","article-title":"Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin\u00ae protein MP0250: A preclinical study","volume":"9","author":"Rao","year":"2018","journal-title":"Oncotarget"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1089\/hum.2017.021","article-title":"Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells","volume":"28","author":"Siegler","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.1038\/s41598-017-07964-5","article-title":"JAM-A overexpression is related to disease progression in diffuse large B-cell lymphoma and downregulated by lenalidomide","volume":"7","author":"Xu","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"9505","DOI":"10.2147\/OTT.S222432","article-title":"Biomarkers Reflecting the Destruction of the Blood-Brain Barrier Are Valuable in Predicting the Risk of Lymphomas with Central Nervous System Involvement","volume":"12","author":"Yu","year":"2019","journal-title":"Onco Targets Ther."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR Pathway in Angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front. Mol. Neurosci."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Goodman, A.M., Choi, M., Wieduwilt, M., Mulroney, C., Costello, C., Frampton, G., Miller, V., and Kurzrock, R. (2017). Next-Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis. Oncol., 1\u201313.","DOI":"10.1200\/PO.16.00004"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Todorovic Balint, M., Jelicic, J., Mihaljevic, B., Kostic, J., Stanic, B., Balint, B., Pejanovic, N., Lucic, B., Tosic, N., and Marjanovic, I. (2016). Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17050683"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3324\/haematol.2013.096248","article-title":"B-cell lymphoma mutations: Improving diagnostics and enabling targeted therapies","volume":"99","author":"Piris","year":"2014","journal-title":"Haematologica"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/bcp.12888","article-title":"Targeting mTOR for the treatment of B cell malignancies","volume":"82","author":"Lee","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1634\/theoncologist.2019-0356","article-title":"CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement","volume":"25","author":"Solimando","year":"2020","journal-title":"Oncologist"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"20563","DOI":"10.18632\/oncotarget.25003","article-title":"Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma","volume":"9","author":"Lamanuzzi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/leu.2017.287","article-title":"JAM-A as a prognostic factor and new therapeutic target in multiple myeloma","volume":"32","author":"Solimando","year":"2018","journal-title":"Leukemia"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1182\/blood-2018-99-117021","article-title":"Central Function for JAM-a in Multiple Myeloma Patients with Extramedullary Disease","volume":"132","author":"Solimando","year":"2018","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1365-2141.1997.d01-2019.x","article-title":"Expression of intercellular adhesion molecule 1 (ICAM-1) in childhood acute lymphoblastic leukaemia: Correlation with clinical features and outcome","volume":"96","author":"Mielcarek","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_141","first-page":"83","article-title":"Lack of adhesion molecules in testicular diffuse centroblastic and immunoblastic B cell lymphomas as a contributory factor in malignant behaviour","volume":"429","author":"Horstmann","year":"1996","journal-title":"Virchows Arch."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1182\/blood-2018-99-117203","article-title":"CIC-Mutation As a Potential Molecular Mechanism of Acquired Resistance to Combined BRAF\/MEK Inhibition in CNS Multiple Myeloma","volume":"132","author":"Solimando","year":"2018","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MOH.0b013e3283623d7f","article-title":"The genetic basis of diffuse large B-cell lymphoma","volume":"20","author":"Pasqualucci","year":"2013","journal-title":"Curr. Opin. Hematol."},{"key":"ref_144","first-page":"3904","article-title":"Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma","volume":"6","author":"Stopeck","year":"2000","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdg057","article-title":"Soluble intercellular adhesion molecule-1 (s-ICAM-1\/s-CD54) in diffuse large B-cell lymphoma: Association with clinical characteristics and outcome","volume":"14","author":"Terol","year":"2003","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Zhang","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/10428194.2016.1228932","article-title":"The significance of FOXP1 in diffuse large B-cell lymphoma","volume":"58","author":"Gascoyne","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood.V128.22.307.307","article-title":"JAM-A as a Prognostic Factor and New Therapeutic Target in Multiple Myeloma","volume":"128","author":"Solimando","year":"2016","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1152\/physrev.00004.2017","article-title":"Junctional Adhesion Molecules (JAMs): Cell Adhesion Receptors With Pleiotropic Functions in Cell Physiology and Development","volume":"97","author":"Ebnet","year":"2017","journal-title":"Physiol. Rev."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1182\/blood-2008-04-152330","article-title":"Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases","volume":"113","author":"Koenen","year":"2009","journal-title":"Blood"},{"key":"ref_151","first-page":"184","article-title":"Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis","volume":"3","author":"Leech","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_152","first-page":"7242","article-title":"Dysregulation of JAM-A plays an important role in human tumor progression","volume":"7","author":"Zhao","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.it.2011.05.005","article-title":"ADAM17: A molecular switch to control inflammation and tissue regeneration","volume":"32","author":"Scheller","year":"2011","journal-title":"Trends Immunol."},{"key":"ref_154","first-page":"137","article-title":"B cell receptor-stimulated mitochondrial phospholipase A2 activation and resultant disruption of mitochondrial membrane potential correlate with the induction of apoptosis in WEHI-231 B cells","volume":"166","author":"Katz","year":"2001","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.toxicon.2016.12.001","article-title":"The small subunit of Hemilipin2, a new heterodimeric phospholipase A2 from Hemiscorpius lepturus scorpion venom, mediates the antiangiogenic effect of the whole protein","volume":"126","author":"Jridi","year":"2017","journal-title":"Toxicon Off. J. Int. Soc. Toxinol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3390\/cancers7020736","article-title":"Lymphoma: Immune evasion strategies","volume":"7","author":"Upadhyay","year":"2015","journal-title":"Cancers"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nrclinonc.2011.31","article-title":"The bone marrow stroma in hematological neoplasms\u2013a guilty bystander","volume":"8","author":"Tripodo","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nrc925","article-title":"Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?","volume":"2","author":"Rafii","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cell.2005.10.036","article-title":"VEGF-induced adult neovascularization: Recruitment, retention, and role of accessory cells","volume":"124","author":"Grunewald","year":"2006","journal-title":"Cell"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3324\/haematol.2013.100818","article-title":"R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: Final MAIN study outcomes","volume":"99","author":"Seymour","year":"2014","journal-title":"Haematologica"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Jiang, L., and Li, N. (2020). B-cell non-Hodgkin lymphoma: Importance of angiogenesis and antiangiogenic therapy. Angiogenesis.","DOI":"10.1007\/s10456-020-09729-7"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_164","doi-asserted-by":"crossref","unstructured":"Antonio, G., Oronzo, B., Vito, L., Angela, C., Antonel-la, A., Roberto, C., Giovanni, S.A., and Antonella, L. (2020). Immune system and bone microenvironment: Rationale for targeted cancer therapies. Oncotarget, 11.","DOI":"10.18632\/oncotarget.27439"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: A single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: A randomized trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin. Immunol. Orlando Fl."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/DDDT.S227477","article-title":"Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study","volume":"14","author":"Ma","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2018.11.012","article-title":"Apatinib exerts anti-tumor activity to non-Hodgkin lymphoma by inhibition of the Ras pathway","volume":"843","author":"Wang","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V106.11.13.13","article-title":"Six, Not Eight Cycles of Bi-Weekly CHOP with Rituximab (R-CHOP-14) Is the Preferred Treatment for Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)","volume":"106","author":"Pfreundschuh","year":"2005","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1869\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:50:15Z","timestamp":1760176215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/7\/1869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":170,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["cancers12071869"],"URL":"https:\/\/doi.org\/10.3390\/cancers12071869","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202007.0168.v1","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]}}}